2015
DOI: 10.1021/am508440j
|View full text |Cite
|
Sign up to set email alerts
|

Red Fluorescent Zinc Oxide Nanoparticle: A Novel Platform for Cancer Targeting

Abstract: Multifunctional zinc oxide (ZnO) nanoparticles (NPs) with well-integrated multimodality imaging capacities have generated increasing research interest in the last decade. However, limited progress has been made in developing ZnO NP-based multimodality tumor-imaging agents. Here we developed novel red fluorescent ZnO NPs and described the successful conjugation of 64Cu (t1/2 = 12.7 h) and TRC105, a chimeric monoclonal antibody against CD105, to these ZnO NPs via well-developed surface engineering procedures. Th… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
61
0
1

Year Published

2015
2015
2022
2022

Publication Types

Select...
9
1

Relationship

2
8

Authors

Journals

citations
Cited by 86 publications
(62 citation statements)
references
References 31 publications
0
61
0
1
Order By: Relevance
“…One common strategy to construct dual-modality imaging agents for PET/optical imaging is radiolabeling fluorescent NPs (for example,Q Ds, [32] ZnO NPs, [33] and UCNPs, [34] ). For example,Q Ds with narrow emission bands tunable from the ultraviolet (UV) to the near-infrared (NIR) regions have been radiolabeled with 18 Fo r 64 Cu, [32] allowing PET/optical dual-modality in vivo imaging from the subcellular scale to the whole body.A nother widely used strategy involves integrating isotopes and fluorescent dyes into the nanoscale matrix of NPs,s uch as organic polymeric NPs, [35] inorganic silica-based NPs, [36] iron oxide NPs, [37] and ferritin nanocages (Figure 4a).…”
Section: Pet/fluorescence Imagingmentioning
confidence: 99%
“…One common strategy to construct dual-modality imaging agents for PET/optical imaging is radiolabeling fluorescent NPs (for example,Q Ds, [32] ZnO NPs, [33] and UCNPs, [34] ). For example,Q Ds with narrow emission bands tunable from the ultraviolet (UV) to the near-infrared (NIR) regions have been radiolabeled with 18 Fo r 64 Cu, [32] allowing PET/optical dual-modality in vivo imaging from the subcellular scale to the whole body.A nother widely used strategy involves integrating isotopes and fluorescent dyes into the nanoscale matrix of NPs,s uch as organic polymeric NPs, [35] inorganic silica-based NPs, [36] iron oxide NPs, [37] and ferritin nanocages (Figure 4a).…”
Section: Pet/fluorescence Imagingmentioning
confidence: 99%
“…The clinical applications of these CuNPs may replace sentinel lymph node biopsy in the near future. Another report described that red fluorescent ZnO NPs conjugated with Cu and a monoclonal antibody (TRC105) could serve as multimodality tumour imaging agents in applications of PET imaging and fluorescence imaging of tumour vasculature (Hong et al 2015). The alloy NPs, FePt of 3, 6 and 12 nm in diameter have been developed as dual modality contrast agent in both MRI and CT imaging due to the excellent magnetic power and stability properties associated along with high capacity of X-ray absorption (Chou et al 2010).…”
Section: Medical Prospects Of Metallic Nanoparticlesmentioning
confidence: 99%
“…Tang et al [16] varied the density of oxygen vacancy and interstitial Zn on the surface of sol-gel derived ZnO NPs via adjusting pH of initial sol solution to change the emission color from green to orange. In addition to popularly observed green and orange emission, red emission ZnO NPs have been rarely reported [17,18].…”
Section: Introductionmentioning
confidence: 99%